Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (2TZ) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (2TZ) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited - Net Assets Trend (None–None)
This chart illustrates how Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (None–None)
The table below shows the annual net assets of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Competitors by Market Cap
The table below lists competitors of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aisino Corp
SHG:600271
|
$1.24 Billion |
|
HARMONIC DRIVE
F:K3R
|
$1.24 Billion |
|
Perpetual Limited
PINK:PPTTF
|
$1.24 Billion |
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR
|
$1.24 Billion |
|
Denka Company Limited
F:DIK
|
$1.24 Billion |
|
NV5 Global Inc
NASDAQ:NVEE
|
$1.24 Billion |
|
Ningbo Shuanglin Auto Parts
SHE:300100
|
$1.24 Billion |
|
Global Ship Lease Inc
NYSE:GSL
|
$1.24 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (2TZ) | €- | N/A | N/A | $1.24 Billion |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |